(Q39860668)

15 September 2017

Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma (English)

1 reference

15 September 2017

1 reference

Lin-Bo Cai

1

1 reference

15 September 2017

Juan Li

2

1 reference

15 September 2017

Ming-Yao Lai

3

1 reference

15 September 2017

Chang-Guo Shan

4

1 reference

15 September 2017

Zong-De Lian

5

1 reference

15 September 2017

Wei-Ping Hong

6

1 reference

15 September 2017

Jun-Jie Zhen

7

1 reference

15 September 2017

Qing Zhou

8

1 reference

15 September 2017

Li-Chao Wang

9

1 reference

15 September 2017

1 April 2013

1 reference

Chinese Journal of Cancer Research

15 September 2017

1 reference

15 September 2017

25

1 reference

15 September 2017

2

1 reference

15 September 2017

206-211

1 reference

Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Advances in the treatment of malignant gliomas

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Malignant gliomas in adults

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

The emerging role of anti-angiogenic therapy for malignant glioma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

All-trans retinoic acid upregulates VEGF expression in glioma cells in vitro

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

Response criteria for phase II studies of supratentorial malignant glioma

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3626981

10.3978/J.ISSN.1000-9604.2013.03.10

20 August 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference

15 September 2017

PubMed publication ID

23592902

1 reference